Pluri Inc (PLUR) Peer Comparison
$0.96
$0.01
(1.05%)
As on 12-Oct-2026 16:00EDT
Market cap
$12 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
306.6
Div. Yield
0 %
Edit
| Pluri Inc (PLUR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
12 | 17,083 | 15,084 | 14,832 | 12,532 |
Revenue ($ Mln) |
1 | 2,782 | 1,054 | 2,436 | 1,664 |
Net Profit ($ Mln) |
-23.82 | 491.50 | 755.85 | 860.62 | 413.60 |
Net Margin (%) |
-2,406.00 | 17.67 | 71.69 | 35.33 | 24.86 |
RoE (%) |
159.46 | 110.09 | -- | 42.98 | 430.03 |
Price to Earnings |
-- | 35.94 | 17.57 | 18.88 | 32.29 |
Price-To-Book |
306.56 | 39.70 | 8.91 | 7.82 | 88.91 |
Income Statement ($ Mln)
| Pluri Inc (PLUR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1.02 | -- | -- | -- | -- |
|
Cost of Revenue
|
0.56 | -- | -- | -- | -- |
|
Gross Profit
|
0.45 | -- | -- | -- | -- |
|
Operating Expenses
|
25.39 | -- | -- | -- | -- |
|
Operating Profit (EBIT)
|
-24.94 | -- | -- | -- | -- |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-25.37 | -- | -- | -- | -- |
|
Provision for Tax
|
-0.03 | -- | -- | -- | -- |
|
Profit after Tax (Net Income)
|
-23.82 | -- | -- | -- | -- |
|
Minority Interest
|
5.60 | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Pluri Inc (PLUR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-23.04 | -- | -- | -- | -- |
|
Minority Interest
|
5.60 | -- | -- | -- | -- |
|
Non-Current Liabilities
|
9.59 | -- | -- | -- | -- |
|
Current Liabilities
|
32.72 | -- | -- | -- | -- |
|
Total Liabilities
|
24.88 | -- | -- | -- | -- |
Assets ($ Mln)
| Pluri Inc (PLUR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
16.15 | -- | -- | -- | -- |
|
Current Assets
|
8.73 | -- | -- | -- | -- |
|
Total Assets
|
24.88 | -- | -- | -- | -- |
|
Total Debt*
|
34.91 | -- | -- | -- | -- |
|
Net Current Assets
|
-23.99 | -- | -- | -- | -- |
Cashflow ($ Mln)
| Pluri Inc (PLUR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-19.59 | -- | -- | -- | -- |
|
Cash Flow from Investing Activities
|
9.90 | -- | -- | -- | -- |
|
Cash from Financing Activities
|
7.04 | -- | -- | -- | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Pluri Inc (PLUR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-121.89 | -- | -- | -- | -- |
|
ROE (%)
|
159.46 | -- | -- | -- | -- |
|
ROA (%)
|
-74.95 | -- | -- | -- | -- |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-2,344.59 | -- | -- | -- | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Pluri Inc (PLUR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.24 | -- | -- | -- | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-5.48 | -- | -- | -- | -- |
|
EPS Growth (%)
|
0.23 | -- | -- | -- | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Pluri Inc (PLUR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.95 | -- | -- | -- | -- |
|
Price / Book Value
|
-0.98 | -- | -- | -- | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-2.04 | -- | -- | -- | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Pluri Inc (PLUR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.52 | -- | -- | -- | -- |
|
Short term debt to equity ratio
|
-1.23 | -- | -- | -- | -- |
|
Current Ratio
|
0.27 | -- | -- | -- | -- |
|
Quick Ratio
|
-- | -- | -- | -- | -- |
|
Interest Coverage
|
-26.76 | -- | -- | -- | -- |
Operating Efficiency Ratios
| Pluri Inc (PLUR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
21.56 | -- | -- | -- | -- |
|
Asset Turnover
|
0.03 | -- | -- | -- | -- |
|
Receivable days
|
169.14 | -- | -- | -- | -- |
|
Inventory Days
|
-- | -- | -- | -- | -- |
|
Payable days
|
508.63 | -- | -- | -- | -- |
|
Cash Conversion Cycle
|
-- | -- | -- | -- | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
